Skip to main content

Table 1 Subgroup analysis of the adverse events (AEs)

From: The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis

FOLFIRINOX vs. control

No. of studies

RR

95%CI

p

Heterogeneity (I2)

Any grade about neuropathy

6

1.12

0.60–2.10

0.72

83

Any grade anemia

8

0.95

0.59–1.52

0.84

94

Any grade decreased appetite

3

1.58

1.08–2.30

0.02

78

Any grade diarrhea

6

2.72

1.60–4.61

<0.001

74

Any grade fatigue

5

1.25

0.92-1.71

0.16

70

Any grade febrile neutropenia

4

2.19

1.04–4.65

0.04

25

Any grade mucositis

2

3.84

2.33–6.34

<0.001

0

Any grade nausea

4

1.94

1.16–3.24

0.01

46

Any grade neutropenia

8

1.15

0.86–1.52

0.35

90

Any grade thrombocytopenia

7

0.76

0.42–1.36

0.36

92

Any grade vomiting

4

1.63

1.26–2.09

<0.001

0

Any grade white blood cell decrease

2

1.54

1.16–2.04

0.003

6

Grade 3 or higher about neuropathy

7

0.85

0.33–2.18

0.73

62

Grade 3 or higher anemia

9

1.21

0.73–2.03

0.46

31

Grade 3 or higher decreased appetite

2

1.41

0.56–3.57

0.47

0

Grade 3 or higher diarrhea

8

3.74

1.62–8.62

0.002

54

Grade 3 or higher elevated ALT

3

0.38

0.21–0.68

0.001

0

Grade 3 or higher fatigue

6

0.95

0.62–1.45

0.80

35

Grade 3 or higher febrile neutropenia

6

2.84

1.35–5.99

0.006

30

Grade 3 or higher mucositis

2

1.34

0.71–2.51

0.37

NA

Grade 3 or higher nausea

4

3.60

1.26–10.30

0.02

11

Grade 3 or higher neutropenia

8

1.67

1.14–2.46

0.009

87

Grade 3 or higher thrombocytopenia

9

1.20

0.74–1.93

0.47

18

Grade 3 or higher vomiting

6

1.46

1.07–1.98

0.02

0

Grade 3 or higher white blood cell decrease

2

3.09

2.00–4.77

<0.001

0

Death

2

0.49

0.20–1.23

0.13

0

  1. RR risk ratio, ALT alanine aminotransferase, NA not applicable
  2. Data in italics are statistically siginificant (P<0.05)